Bio-Rad Laboratories has extended its range of recombinant monoclonal anti-idiotypic antibodies with the introduction of antibodies that are specific for ipilimumab (Yervoy) and the ipilimumab/CTLA-4 drug-target complex. These highly specific and high-affinity antibodies are suitable for bioanalytical and patient drug level monitoring assays for the immune checkpoint inhibitor, ipilimumab. Bio-Rad offers a portfolio of recombinant, monoclonal anti-idiotypic antibodies and drug-target complex binders for the development of highly selective and sensitive assays.

Bio-Rad Laboratories